SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

PROK

ProKidney
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock will trade on PROACT 1 enrollment milestones and the Q2 2027 topline readout, not quarterly financials. Monitor for enrollment completion announcements in mid-2026 and any FDA interactions. Cash runway into mid-2027 provides no near-term financing urgency, but the burn rate implies a potential capital raise before the readout if enrollment delays occur.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.66
T+0 close · May 15, 2026 · via day close
Latest settled
−3.01%
T+60 · $1.61
Vs SPY
−7.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $1.66entry
  2. T+1 · 6mo ago −3.01%α −2.95% · $1.61
  3. T+5 · 6mo ago +5.42%α +4.46% · $1.75
  4. T+20 · 5mo ago +0.60%α −1.52% · $1.67
  5. T+60 · 3mo ago −3.01%α −7.53% · $1.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible revenue of $226K. The key catalyst is the on-track enrollment completion for the Phase 3 PROACT 1 accelerated approval analysis in mid-2026, with pivotal topline eGFR slope results expected in Q2 2027. Cash burn continues, with $224.9M in cash supporting operations into mid-2027, but no fundamental financial improvement was reported.

Key Financial Metrics

EPS
−$0.14
est −$0.14 · -1.8%
Revenue
$226.0K
est $100.0K · +126.0% · -1.7% YoY
Rating
in line

Key Facts

  • Q1 2026 EPS of -$0.14 vs consensus -$0.14 (in line, 1.8% miss)
  • Revenue of $226K vs consensus $100K (beat, but immaterial for a clinical-stage biotech)
  • Cash, cash equivalents and marketable securities: $224.9M as of March 31, 2026, down from $270.0M at year-end 2025
  • Net loss before noncontrolling interest: $42.6M in Q1 2026 vs $38.0M in Q1 2025
  • R&D expenses increased to $33.8M from $27.3M YoY, driven by PROACT 1 study costs
  • Phase 3 PROACT 1 enrollment on track to complete in mid-2026; pivotal topline results expected Q2 2027
  • FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation
  • Phase 2 REGEN-007 results published in CJASN in January 2026
  • Cash runway into mid-2027

Financial Impact

No material financial impact from Q1 results; cash burn of ~$45M per quarter continues. Key value driver is the PROACT 1 readout in Q2 2027.

cashnet lossR&D expenses

Risk Factors

  • PROACT 1 enrollment delays or failure to meet eGFR slope endpoint
  • Cash burn may require dilutive financing before mid-2027 if enrollment or readout is delayed
  • Regulatory risk: FDA may require additional studies beyond PROACT 1 for approval
  • Competition from other CKD therapies (SGLT2 inhibitors, finerenone)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296021

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026